XML 83 R69.htm IDEA: XBRL DOCUMENT
v3.20.2

Fair Value Considerations (Details 5) - USD ($) | Jun. 30, 2020 | Jun. 30, 2019
--- | --- | ---
MiOXSYS patent (Luoxis patents) | $ 11,081,048 | $ 220,611
Fair Value, Measurements, Nonrecurring |  |
MiOXSYS patent (Luoxis patents) | 0 |
Debt | 982,076 |
Total | 96,410,697 |
Level 1 | Fair Value, Measurements, Nonrecurring |  |
MiOXSYS patent (Luoxis patents) | 0 |
Debt | 0 |
Total | 0 |
Level 2 | Fair Value, Measurements, Nonrecurring |  |
MiOXSYS patent (Luoxis patents) | 0 |
Debt | 0 |
Total | 0 |
Level 3 | Fair Value, Measurements, Nonrecurring |  |
MiOXSYS patent (Luoxis patents) | 0 |
Debt | 982,076 |
Total | 96,410,697 |
Cerecor, Inc. | Fair Value, Measurements, Nonrecurring |  |
Product technology rights | 22,700,000 |
Goodwill | 19,453,135 |
Fixed payment arrangements | 29,837,853 |
Cerecor, Inc. | Level 1 | Fair Value, Measurements, Nonrecurring |  |
Product technology rights | 0 |
Goodwill | 0 |
Fixed payment arrangements | 0 |
Cerecor, Inc. | Level 2 | Fair Value, Measurements, Nonrecurring |  |
Product technology rights | 0 |
Goodwill | 0 |
Fixed payment arrangements | 0 |
Cerecor, Inc. | Level 3 | Fair Value, Measurements, Nonrecurring |  |
Product technology rights | 22,700,000 |
Goodwill | 19,453,135 |
Fixed payment arrangements | 29,837,853 |
Innovus Pharmaceuticals | Fair Value, Measurements, Nonrecurring |  |
Customer lists | 390,000 |
Product distribution rights (trademarks and patents) | 11,354,000 |
Goodwill | 8,637,272 |
Notes payable | 3,056,361 |
Innovus Pharmaceuticals | Level 1 | Fair Value, Measurements, Nonrecurring |  |
Customer lists | 0 |
Product distribution rights (trademarks and patents) | 0 |
Goodwill | 0 |
Notes payable | 0 |
Innovus Pharmaceuticals | Level 2 | Fair Value, Measurements, Nonrecurring |  |
Customer lists | 0 |
Product distribution rights (trademarks and patents) | 0 |
Goodwill | 0 |
Notes payable | 0 |
Innovus Pharmaceuticals | Level 3 | Fair Value, Measurements, Nonrecurring |  |
Customer lists | 390,000 |
Product distribution rights (trademarks and patents) | 11,354,000 |
Goodwill | 8,637,272 |
Notes payable | $ 3,056,361 |

X
- References No definition available. + Details
Name: | AYTU_FiniteLivedProductTechnologyRightsGross
Namespace Prefix: | AYTU_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | AYTU_FixedPaymentArrangementsFairValue
Namespace Prefix: | AYTU_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611 + Details
Name: | us-gaap_DebtInstrumentFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value of asset after deduction of liability. + References No definition available. + Details
Name: | us-gaap_FairValueNetAssetLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Gross carrying amount before accumulated amortization as of the balance sheet date of an asset comprised of customer information, acquired in a business combination or other transaction, having a finite beneficial life. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedCustomerListsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedPatentsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Gross carrying amount before accumulated amortization as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a specified period of time. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedTrademarksGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value portion of asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_GoodwillFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value portion of notes payable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20,22) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_NotesPayableFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=AYTU_CerecorIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=AYTU_InnovusPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |